Format

Send to

Choose Destination
Patient. 2016 Apr;9(2):149-59. doi: 10.1007/s40271-015-0134-z.

What Matters to Women When Making Decisions About Breast Cancer Chemoprevention?

Author information

1
Ann Arbor VA Center for Clinical Management Research, Building 16, 4th Floor, 2800 Plymouth Road, Ann Arbor, MI, 48105, USA. katiemartinez@gmail.com.
2
Ann Arbor VA Center for Clinical Management Research, Building 16, 4th Floor, 2800 Plymouth Road, Ann Arbor, MI, 48105, USA.
3
Division of General Medicine, University of Michigan, Ann Arbor, MI, USA.
4
Department of Family and Emergency Medicine and Office of Education and Continuing Professional Development, Laval University, Quebec City, QC, Canada.
5
Population Health and Optimal Health Practices Research Unit, CHU de Qu├ębec Research Centre, Quebec City, QC, Canada.
6
Berlin School of Public Health, Berlin, Germany.

Abstract

PURPOSE:

Despite the effectiveness of chemoprevention (tamoxifen and raloxifene) in preventing breast cancer among women at high risk for the disease, uptake is low. The objective of this study was to determine the tradeoff preferences for various attributes associated with chemoprevention among women not currently taking the drugs.

METHODS:

We used rating-based conjoint analysis to evaluate the relative importance of a number of attributes associated with chemoprevention, including risk of side effects, drug effectiveness, time needed to take the drugs, and availability of a blood test to see if the drugs were working in an Internet sample of women. We generated mean importance values and part-worth utilities for all attribute levels associated with taking chemoprevention. We then used multivariable linear regression to examine attribute importance scores controlling for participant age, race, Hispanic ethnicity, educational level, and a family history of breast cancer.

RESULTS:

Overall interest in taking chemoprevention was low among the 1094 women included in the analytic sample, even for the scenario in which participants would receive the greatest benefit and fewest risks associated with taking the drugs. Time needed to take the pill for it to work and 5-year risk of breast cancer were the most important attributes driving tradeoff preferences between the chemoprevention scenarios.

CONCLUSIONS:

Interest in taking chemoprevention among this sample of women at average risk was low. Addressing women's concerns about the time needed to take chemoprevention for it to work may help clinicians improve uptake of the drugs among those likely to benefit.

PMID:
26115846
PMCID:
PMC5513503
DOI:
10.1007/s40271-015-0134-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center